MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Stock Quote (indian pharma)
- ALEMBIC PHARMA
ALEMBIC PHARMA Share Price (APLL)
Here is the latest stock price and chart of ALEMBIC PHARMA. For more details, see the ALEMBIC PHARMA company fact sheet and quarterly results. For a sector overview, read our pharmaceuticals sector report. Since small-cap stocks interest you, here's a proven approach on investing in small-cap stocks.
Free Signup: Learn how India is poised to emerge as a global power
| Live BSE Quotes | Oct 29, 2020 09:40:00 AM | ||
|---|---|---|---|
| Price (Rs)958.60 | Open (Rs) 946.10 | High (Rs) 960.95 | Low (Rs) 946.10 |
| % Change-0.44 | Volume 709 | Value (Rs) 679,647 | 52-Week H/L 1,128.00 / 436.10 |
| Live NSE Quotes | Oct 29, 2020 9:44:59 AM | ||
|---|---|---|---|
| Price (Rs)959.70 | Open (Rs) 950.00 | High (Rs) 962.00 | Low (Rs) 942.20 |
| % Change-0.36 | Volume 22,342 | Value (Rs) 21,398,274 | 52-Week H/L 1,128.90 / 434.80 |
| Change | |||||
|---|---|---|---|---|---|
| 1 Day -0.44% | 1 Month 0.92% | 3 Months -2.26% | 1 Year 76.72% | 5 Years (CAGR)* 7.12% | |
* Compound Annual Growth Rate
| Valuation | |||
|---|---|---|---|
| EPS (Rs)* 55.66 | P/E Ratio (x) 17.22 | Market Cap (Rs m) 180,715.27 | P/BV (x) 6.65 |
| *Trailing 12 months earnings, excluding extraordinary / exceptional items. | BSE Sensex | CNX Nifty |
- Charts
-
S&P BSE SENSEX 
PERIOD - Advanced Charts new
- Charts by TradingView
ALEMBIC PHARMA Share Price Today:
ALEMBIC PHARMA share price is down 0.4% to Rs 958.6 on the BSE. On the NSE, the ALEMBIC PHARMA share price is down 0.4% to Rs 959.7. The total volume of shares traded is 0.0 m.
Overall, the broader S&P BSE HEALTHCARE Index is trading down by 0.6%. And the benchmark S&P BSE SENSEX is at 39,724.9 (down 0.5%).
Over the last 30 days, the ALEMBIC PHARMA share price is down 2.7%. And over the last one year, ALEMBIC PHARMA share price is up 77.7%.
What else is happening in the markets today? Dig in...
- TRACK NOW:
- Most Active Stocks Rs 0 to 10
- Most Active Stocks Rs 10 to 20
- Top Gainers Today BSE A Group
- Top Gainers Today NSE Above Rs 20
- Top Gainers Today BSE Above Rs 20
- Top Gainers Today BSE Sensex
- Top Gainers Today BSE Small Cap
- Top Gainers Today BSE 500
- Top Losers Today BSE A Group
- Most Active Stocks Rs 1 to 2
- Top Losers Today NSE Above Rs 20
- Buzzing Stocks Today
- Most Popular Stocks BSE 30
Today's Market
SGX Nifty Down 62 Points, Factors Behind the Stock Market Crash, September Quarter Results, and Top Buzzing Stocks Today(Pre-Open)
Indian share markets witnessed a sharp sell-off yesterday and ended their session deep in the red.
Related Views On News
ALEMBIC PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 30.0% (Quarterly Result Update)
Oct 23, 2020 | Updated on Oct 23, 2020For the quarter ended September 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 30.0% YoY). Sales on the other hand came in at Rs 15 bn (up 17.4% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.
ALEMBIC PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 33.3% (Quarterly Result Update)
Jan 23, 2020 | Updated on Jan 23, 2020For the quarter ended December 2019, ALEMBIC PHARMA has posted a net profit of Rs 2 bn (up 33.3% YoY). Sales on the other hand came in at Rs 12 bn (up 18.8% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.
ALEMBIC PHARMA 2018-19 Annual Report Analysis (Annual Result Update)
Jun 13, 2019 | Updated on Jun 13, 2019Here's an analysis of the annual report of ALEMBIC PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.
ALEMBIC PHARMA 2017-18 Annual Report Analysis (Annual Result Update)
Dec 21, 2018 | Updated on Dec 21, 2018Here's an analysis of the annual report of ALEMBIC PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.
More Views on NewsMost Popular
My View on ITC (Fast Profits Daily)
Oct 23, 2020What do the charts say about ITC?
PSU Banks Will Move Up Again (Profit Hunter)
Oct 27, 2020My charts tell me PSU banks are set for a rebound.
One of the Best Investment Opportunities in the Market Right Now (Fast Profits Daily)
Oct 16, 2020The one sector that you should be looking at to make good profits.
Why India's Drone Revolution is a 4x Profit Opportunity (Profit Hunter)
Oct 16, 2020My research on India's leading defence companies brought me to one major player in drone manufacturing.
MoreOUR TOP 5 IDEAS
- Free Report: Multibagger Stock Ideas 2021
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
- Free Report: The Secret to Increasing Your Trading Profits Daily!
- No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.
TRACK ALEMBIC PHARMA
- Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON ALEMBIC PHARMA
ALEMBIC PHARMA - MYLAN COMPARISON
COMPARE ALEMBIC PHARMA WITH
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.